Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 14.08 percent decrease over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $1.32 million which beat the analyst consensus estimate of $859.70 thousand by 54.12 percent. This is a 189.93 percent increase over sales of $457.00 thousand the same period last year.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。
没有相关数据
如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”